OPA1 Deficiency Impairs NGF Signaling and Drives Sympathetic Neurodegeneration

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2026-02-01 Epub Date: 2026-02-23 DOI:10.1016/j.jacbts.2025.101460

Marco Ronfini PhD , Valentina Prando PhD , Vittoria Di Mauro PhD , Lolita Dokshokova PhD , Erika Lazzeri PhD , Irene Costantini PhD , Lukas Alàn PhD , Erwan Andre Riviere PhD , Alex Incensi BSc , Camilla Olianti PhD , Chiara La Morgia MD, PhD , Rocco Liguori MD , Leonardo Sacconi PhD , Vincenzo Donadio MD, PhD , Luca Scorrano MD, PhD , Valerio Carelli MD, PhD , Marco Mongillo MD, PhD , Tania Zaglia PhD

{"title":"OPA1 Deficiency Impairs NGF Signaling and Drives Sympathetic Neurodegeneration","authors":"Marco Ronfini PhD , Valentina Prando PhD , Vittoria Di Mauro PhD , Lolita Dokshokova PhD , Erika Lazzeri PhD , Irene Costantini PhD , Lukas Alàn PhD , Erwan Andre Riviere PhD , Alex Incensi BSc , Camilla Olianti PhD , Chiara La Morgia MD, PhD , Rocco Liguori MD , Leonardo Sacconi PhD , Vincenzo Donadio MD, PhD , Luca Scorrano MD, PhD , Valerio Carelli MD, PhD , Marco Mongillo MD, PhD , Tania Zaglia PhD","doi":"10.1016/j.jacbts.2025.101460","DOIUrl":null,"url":null,"abstract":"<div><div>Peripheral sympathetic neurodegeneration drives cardiac dysfunction in dominant optic atrophy, revealing a critical neuro-cardiac link. Optic atrophy factor-1 haploinsufficiency disrupts mitochondrial dynamics and neurotrophic signaling, causing targeted sympathetic denervation and arrhythmias. Restoring nerve growth factor transport and mitochondrial health in sympathetic neurons represents a promising therapeutic avenue for cardiac autonomic disorders. Future research must unravel mechanisms of neurocardiac crosstalk to develop precise interventions against neurogenic cardiac disease progression.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"11 2","pages":"Article 101460"},"PeriodicalIF":8.4000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X25004139","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Peripheral sympathetic neurodegeneration drives cardiac dysfunction in dominant optic atrophy, revealing a critical neuro-cardiac link. Optic atrophy factor-1 haploinsufficiency disrupts mitochondrial dynamics and neurotrophic signaling, causing targeted sympathetic denervation and arrhythmias. Restoring nerve growth factor transport and mitochondrial health in sympathetic neurons represents a promising therapeutic avenue for cardiac autonomic disorders. Future research must unravel mechanisms of neurocardiac crosstalk to develop precise interventions against neurogenic cardiac disease progression.

查看原文本刊更多论文

OPA1缺乏损害NGF信号传导并驱动交感神经变性。

周围交感神经退行性变在显性视神经萎缩中驱动心功能障碍，揭示了一个关键的神经-心脏联系。视神经萎缩因子-1单倍体功能不全破坏线粒体动力学和神经营养信号，引起定向交感神经去支配和心律失常。恢复神经生长因子转运和线粒体健康在交感神经元是一个有前途的治疗途径心脏自主神经疾病。未来的研究必须揭示神经心脏串扰的机制，以制定针对神经源性心脏病进展的精确干预措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.